TY - THES A1 - Simon, Martin T1 - Retrospektive Analyse prognostischer Faktoren nach Leberresektion bei primären und sekundären Lebertumoren 1995 bis 2003 T1 - Retrospective analysis of prognostic parameters after liver resection of primary and secondary liver tumors N2 - In der vorliegenden Arbeit wurden die Krankengeschichten von 93 Patienten mit sekundären Lebertumoren kolorektaler Karzinome und von 39 Patienten mit Hepatozellulären Karzinomen aufgearbeitet, die im Zeitraum 1995 bis 2003 an der Chirurgischen Universitätsklinik Würzburg in kurativer Absicht operiert wurden. Es konnte eine umfassende Darstellung der epidemiologischen Daten, der Tumorstadien sowie der operativen und postoperativen Verläufe erreicht werden. Als prognostisch ungünstige Faktoren für das Langzeitüberleben der Patienten mit Lebermetastasen kolorektaler Karzinome konnten ein CEA-Wert von mehr als 16,8 ng/ml und ein Sicherheitsabstand von weniger als 5 mm identifiziert werden. Kein Zusammenhang fand sich mit dem Diagnosezeitpunkt der Metastasierung, der Art der Resektion und dem Alter der Patienten. Ebenfalls konnte kein statistisch signifikanter Zusammenhang zwischen Staging, Grading und Lokalisation des Primärtumors nachgewiesen werden. Bei den Patienten mit Hepatozellulären Karzinomen wurden das Alter, der Zirrhosegrad der Leber, die Größe des Tumors und die Höhe des Tumormarkers AFP als signifikante Faktoren für das Langzeitüberleben gefunden. Die Art der Resektion zeigt eine deutliche Tendenz zur Signifikanz und scheint ebenfalls einen Einfluss auf das Outcome der Patienten zu haben. Insgesamt konnte nachgewiesen werden, dass die Leberresektion primärer und sekundärer Lebertumoren ein sicheres Operationsverfahren mit niedriger Morbidität und Mortalität ist, das das Überleben der Patienten signifikant verlängert. Offen bleibt, wie sich die Therapie des hepatozellulären Karzinoms vor dem Hintergrund der Lebertransplantation weiterentwickeln wird. Zum einen stellt die Transplantation ein Verfahren dar, bei dem höhere Überlebenszeiten und längere tumorfreie Intervalle erreicht werden können, zum anderen ist der bestehende Mangel an Spendeorganen momentan das größte Problem, um jedem Patienten, der ein Kandidat zur Transplantation wäre, ein Organ zur Verfügung zu stellen. N2 - In this study, 93 patients with secondary liver tumors of colorektal cancer and of 39 patients with hepatocellular carcinoma were analyzed, who underwent operation between 1995 and 2003 in the "Chirurgische Universitätsklink Würzburg". Epidemiological data, tumor stages and intraoperative and postoperative processes are described in this study. A CEA level of more than 16,8 ng/ml and a safety margin of less than 5 mm were identified as prognostically unfavorable factors for long time survival for patients with liver metastases of colorektal cancer. Time of diagnosis, resection technique and the patients age did not correlate with survival. Staging, grading and localisation of the primary tumor did not correlate either. Age, grade of cirrhosis, size of tumor and AFP-level of patients with hepatocellular carcinoma were determined as significant factors for long term survival. The resection technique showed an obvious tendency to significance and seemed to have an influence on patients outcome. In summary this study proved, that liver resection of primary and secondary liver tumors is a safe procedure with low morbidity and mortality, that significantly prolongs patients survival. However the therapy of hepatocellular carcinoma including liver transplantation remains to be focused on. On the one hand transplantation is a procedure that prolongs patientssurvival and reaches longer tumor free intervalls. On the other hand the lack of organs is the biggest problem to offer every candidate an organ. KW - Leberkrebs KW - Lebermetastase KW - Colonkrebs KW - Fetoprotein KW - Carcino-embryonales Antigen KW - liver metastases KW - hepatocellular carcinoma KW - colorektal cancer KW - afp KW - cea Y1 - 2008 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-37102 ER - TY - JOUR A1 - Leyh, Catherine A1 - Ehmer, Ursula A1 - Roessler, Daniel A1 - Philipp, Alexander B. A1 - Reiter, Florian P. A1 - Jeliazkova, Petia A1 - Jochheim, Leonie S. A1 - Jeschke, Matthias A1 - Hammig, Janina A1 - Ludwig, Johannes M. A1 - Theysohn, Jens M. A1 - Geier, Andreas A1 - Lange, Christian M. T1 - Sorafenib versus lenvatinib-based sequential systemic therapy for advanced hepatocellular carcinoma: a real-world analysis JF - Cancers N2 - The optimal treatment sequence of tyrosine kinase inhibitor (TKI)-based therapy in patients with hepatocellular carcinoma (HCC) remains unclear. Therefore, sequential systemic therapy after first-line therapy with sorafenib or lenvatinib was compared in a retrospective real-world cohort. In total, 164 patients with HCC were included. Child B cirrhosis was present in 26 patients (16.5%), whereas 132 patients (83.5%) had preserved liver function. In total, 72 patients (44%) discontinued systemic therapy after first-line therapy while 51 (31%) and 31 (19%) patients received 2 or more treatment lines. Most notably, median overall survival (mOS) was influenced by liver functional status and patient performance status at the beginning of first-line therapy. Patients receiving a sequential therapy regimen had significantly longer mOS compared to patients that discontinued systemic therapy after omitting first-line treatment. The choice of the initial TKI did not impact mOS. A clear deterioration of liver function could be observed during the course of TKI-based treatment. KW - hepatocellular carcinoma KW - systemic therapy KW - tyrosine-kinase inhibitor Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-270765 SN - 2072-6694 VL - 14 IS - 8 ER - TY - JOUR A1 - Baur, Johannes A1 - Ritter, Christian O. A1 - Germer, Christoph-Thomas A1 - Klein, Ingo A1 - Kickuth, Ralph A1 - Steger, Ulrich T1 - Transarterial chemoembolization with drug-eluting beads versus conventional transarterial chemoembolization in locally advanced hepatocellular carcinoma JF - Hepatic Medicine N2 - Purpose: In hepatocellular carcinoma patients with large or multinodal tumors, where curative treatment options are not feasible, transarterial therapies play a major role. Transarterial chemoembolization (TACE) with drug-eluting beads (DEB-TACE) is a promising new approach due to higher intratumoral and lower systemic concentration of the chemotherapeutic agent compared to conventional TACE (cTACE). Patients and methods: In a retrospective analysis, 32 patients with hepatocellular carcinoma who received either DEB or a cTACE were compared regarding survival time, disease recurrence, and side effects such as pain and fever. Results: No significant differences could be detected between the cTACE and DEB-TACE groups with regard to mean hospital stay, appearance of postinterventional fever, or 30-day mortality. However, the application of intravenous analgesics as postinterventional pain medication was needed more often in patients treated with DEB-TACE (57.1% vs 12.5%, P=0.0281). The overall median survival after the initial procedure was 10.8 months in the cTACE group and 9.2 months in the DEB-TACE group, showing no significant difference. Conclusion: No survival benefit for patients treated with either DEB-TACE or cTACE was observed. Surprisingly, a higher rate of postinterventional pain could be detected after DEB-TACE. KW - transarterial chemoembolization KW - hepatocellular carcinoma KW - drug-eluting beads Y1 - 2016 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-146553 VL - 2016 IS - 8 ER -